查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1936603

生物反应器市场机会、成长要素、产业趋势分析及2026年至2035年预测

Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球生物反应器市场预计到 2025 年将达到 138 亿美元，到 2035 年将达到 389 亿美元，年复合成长率为 11.2%。

生物反应器市场-IMG1

这一增长主要得益于製药和生物技术行业的扩张、生物反应器系统的技术创新以及对个人化医疗和先进治疗方法日益增长的需求。生物反应器在疫苗、单株抗体和细胞疗法的生产中发挥核心作用，而慢性病的增加和对创新治疗方法的追求推动了这些产品需求的成长。基因工程、再生医学和生物相似药的进步，促使企业需要扩充性、高效且符合监管规定的生物反应器系统，以支援大规模生产并维持产品品质。各公司正专注于生物製剂和孤儿药的研发，这些药物用于治疗罕见疾病，并利用监管激励措施，投资于一次性系统、自动化平台和其他先进的生物反应器技术。这些因素共同作用，使生物反应器成为现代生物製造不可或缺的一部分。

市场覆盖范围
开始年份 2025
预测年份 2026-2035
起始值 138亿美元
预测金额 389亿美元
复合年增长率 11.2%

预计到2025年，可重复使用生物反应器市场规模将达到100亿美元。由于其成本效益高，可重复使用生物反应器是大规模生产的首选，因为它们可以进行灭菌并重复用于多个生产週期。其耐用性和多功能性使其能够在各种生产条件下运行，这对于生物製药生产中高产量、复杂的製程至关重要。这些特性使可重复使用系统成为高效生物製药生产的基础，在生物製剂生产中，在不影响品质的前提下管理大量生产至关重要。

预计到2025年，哺乳动物细胞市场规模将达到103亿美元。哺乳动物细胞因其能够模拟人类细胞的行为，确保治疗的安全性和有效性，而被广泛用于生产单株抗体、重组蛋白和疫苗等复杂生物製药。这些细胞对温度、pH值、氧气浓度和营养供应等环境参数高度敏感。生物反应器能够提供可控的培养条件，从而优化细胞生长和生产力，使其成为开发先进治疗方法的关键设备。

预计到2025年，美国生物反应器市场规模将达47亿美元。这一成长主要得益于美国先进的製药和生物技术产业、生物製药投资的不断增加以及个人化医疗的日益普及。生物反应器能够实现疫苗、单株抗体和基因疗法的高品质、大规模生产，从而支持美国产业向先进生物製药和先进治疗方案的转型。

目录

第一章调查方法和范围

第二章执行摘要

第三章业界考察

  • 生态系分析
  • 产业影响因素
    • 司机
      • 不断发展的製药和生物技术产业
      • 生物反应器的技术进步
      • 人们越来越关注罕见疾病药物的研发
      • 对个人化医疗的需求日益增长
    • 产业潜在风险与挑战
      • 低容量一次性生物反应器
      • 可萃取物和可浸出物问题
    • 市场机会
      • 用于新型医疗应用的精准发酵技术
  • 成长潜力分析
  • 监管环境
  • 技术进步
    • 当前技术趋势
    • 新兴技术
  • 2024年定价分析
  • 未来市场趋势
  • 波特五力分析
  • PESTEL 分析

第四章 竞争情势

  • 介绍
  • 公司市占率分析
  • 企业矩阵分析
  • 主要市场公司的竞争分析
  • 竞争定位矩阵
  • 重大进展
    • 併购
    • 合作伙伴关係和合资企业
    • 新产品发布
    • 扩张计划

第五章 依产品类型分類的市场估算与预测，2022-2035年

  • 一次性（塑胶）
  • 可重复使用的

第六章 依电池类型分類的市场估计与预测，2022-2035年

  • 哺乳动物细胞
  • 细菌细胞
  • 酵母菌细胞
  • 其他细胞

7. 2022-2035年按分子分類的市场估计与预测

  • 单株抗体
  • 疫苗
  • 重组蛋白
  • 干细胞
  • 基因治疗
  • 其他分子

第八章 按应用领域分類的市场估算与预测，2022-2035年

  • 研发阶段、非临床阶段及临床试验阶段
  • 商业生产

第九章 按材料分類的市场估算与预测，2022-2035年

  • 不銹钢
  • 玻璃
  • 一次性的

第十章 依产能分類的市场估计与预测，2022-2035年

  • 少于500公升
  • 501至5000公升
  • 超过5000公升

第十一章 依最终用途分類的市场估计与预测，2022-2035年

  • 研究与发展研究所
  • 生物製药製造商
  • 契约製造组织（CMO）

第十二章 2022-2035年各地区市场估算与预测

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国

第十三章：公司简介

  • Altrad Group
  • BaiLun Biotechnology Co., Ltd
  • Bbi-biotech
  • Cellexus
  • CerCell A/S
  • Danaher Corporation
  • Donaldson Company, Inc
  • Eppendorf Group
  • Esco Micro Pte. Ltd.
  • GEA Group Aktiengesellschaft
  • Getinge AB
  • Merck KGaA
  • PBS Biotech, Inc.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 141

The Global Bioreactors Market was valued at USD 13.8 billion in 2025 and is estimated to grow at a CAGR of 11.2% to reach USD 38.9 billion by 2035.

Bioreactors Market - IMG1

The growth is fueled by the expansion of the pharmaceutical and biotechnology sectors, technological innovations in bioreactor systems, and increasing demand for personalized and advanced therapies. Bioreactors are central to the manufacturing of vaccines, monoclonal antibodies, and cell-based therapies, which are experiencing high demand due to the rising prevalence of chronic diseases and the pursuit of innovative treatment options. Advancements in genetic engineering, regenerative medicine, and biosimilars are driving the need for scalable, efficient, and compliant bioreactor systems capable of supporting large-scale production while maintaining product quality. Investment in single-use systems, automated platforms, and other advanced bioreactor technologies is intensifying as companies focus on biologics and orphan drugs, which are increasingly developed to address rare diseases under supportive regulatory incentives. These factors collectively make bioreactors indispensable in modern biomanufacturing.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$13.8 Billion
Forecast Value$38.9 Billion
CAGR11.2%

The reusable bioreactor segment reached USD 10 billion in 2025. Reusable bioreactors are preferred for large-scale production due to their cost-effectiveness, as they can be sterilized and reused across multiple production cycles. Their durability and versatility allow operations under diverse manufacturing conditions, which is critical for high-yield, complex processes in biopharmaceutical production. These features make reusable systems a cornerstone for efficient biologics manufacturing, where managing large batch volumes without compromising quality is essential.

The mammalian cell segment captured USD 10.3 billion in 2025. Mammalian cells are extensively utilized in producing complex biologics, including monoclonal antibodies, recombinant proteins, and vaccines, because they replicate human cellular behavior, ensuring therapeutic safety and efficacy. These cells are highly sensitive to environmental parameters such as temperature, pH, oxygen concentration, and nutrient availability. Bioreactors provide controlled conditions that optimize cell growth and productivity, making them indispensable in the development of advanced therapies.

U.S. Bioreactors Market was valued at USD 4.7 billion in 2025. The expansion is driven by the country's advanced pharmaceutical and biotechnology sectors, increasing investment in biologics, and rising adoption of personalized medicine. Bioreactors facilitate high-quality, large-scale production of vaccines, monoclonal antibodies, and gene therapies, supporting the U.S. industry's shift toward sophisticated biologics and advanced therapeutic solutions.

Leading players in the Global Bioreactors Market include Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Eppendorf Group, GEA Group Aktiengesellschaft, Altrad Group, Cellexus, CerCell A/S, Donaldson Company, Inc., BaiLun Biotechnology Co., Ltd, Bbi-biotech, Esco Micro Pte. Ltd., and PBS Biotech, Inc. Market participants are focusing on strategies such as expanding global production capacity, integrating automation, and developing next-generation single-use and modular bioreactor systems. Companies are investing in R&D to improve bioreactor efficiency, scalability, and compliance with stringent regulatory standards. Strategic partnerships and acquisitions help strengthen regional presence, secure critical raw material supply chains, and diversify product portfolios. Firms are also leveraging digital technologies, AI-driven process control, and real-time monitoring systems to enhance productivity and operational efficiency.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product type trends
    • 2.2.3 Cell trends
    • 2.2.4 Molecule trends
    • 2.2.5 Usage trends
    • 2.2.6 Material trends
    • 2.2.7 Size trends
    • 2.2.8 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing pharmaceutical and biotechnology industry
      • 3.2.1.2 Technological advancements in bioreactors
      • 3.2.1.3 Growing focus on orphan drug development
      • 3.2.1.4 Rising demand for personalized medicines
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Low capacity of single-use bioreactors
      • 3.2.2.2 Concerns regarding extractables and/or leachables
    • 3.2.3 Market opportunities
      • 3.2.3.1 Precision fermentation for novel healthcare applications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Pricing analysis, 2024
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Single-use (Plastic)
  • 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Cell, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Mammalian cells
  • 6.3 Bacterial cells
  • 6.4 Yeast cells
  • 6.5 Other cells

Chapter 7 Market Estimates and Forecast, By Molecule, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Monoclonal antibodies
  • 7.3 Vaccines
  • 7.4 Recombinant proteins
  • 7.5 Stem cells
  • 7.6 Gene therapy
  • 7.7 Other molecules

Chapter 8 Market Estimates and Forecast, By Usage, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Developmental, pre-clinical & clinical
  • 8.3 Commercial production

Chapter 9 Market Estimates and Forecast, By Materials, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 Stainless steel
  • 9.3 Glass
  • 9.4 Single-use

Chapter 10 Market Estimates and Forecast, By Size, 2022 - 2035 ($ Mn)

  • 10.1 Key trends
  • 10.2 Less than 500 L
  • 10.3 501-5,000 L
  • 10.4 More than 5,000 L

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 11.1 Key trends
  • 11.2 R&D organizations
  • 11.3 Biopharma manufacturers
  • 11.4 Contract manufacturing organizations (CMOs)

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 12.1 Key trends
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 France
    • 12.3.4 Spain
    • 12.3.5 Italy
    • 12.3.6 Netherlands
  • 12.4 Asia Pacific
    • 12.4.1 China
    • 12.4.2 India
    • 12.4.3 Japan
    • 12.4.4 Australia
    • 12.4.5 South Korea
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Argentina
  • 12.6 Middle East and Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 South Africa
    • 12.6.3 UAE

Chapter 13 Company Profiles

  • 13.1 Altrad Group
  • 13.2 BaiLun Biotechnology Co., Ltd
  • 13.3 Bbi-biotech
  • 13.4 Cellexus
  • 13.5 CerCell A/S
  • 13.6 Danaher Corporation
  • 13.7 Donaldson Company, Inc
  • 13.8 Eppendorf Group
  • 13.9 Esco Micro Pte. Ltd.
  • 13.10 GEA Group Aktiengesellschaft
  • 13.11 Getinge AB
  • 13.12 Merck KGaA
  • 13.13 PBS Biotech, Inc.
  • 13.14 Sartorius AG
  • 13.15 Thermo Fisher Scientific Inc.